FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897548738> ?p ?o ?g. }

• W2897548738 abstract "IgE is the key mediator of allergic responses. Omalizumab, an IgE-specific monoclonal antibody that depletes IgE, is effective for treating severe allergic asthma. The need for frequent administration of the expensive drug, however, limits its applications. Taking advantage of T cell memory, adoptive T cell therapy (ACT) targeting IgE-producing cells has the potential to achieve long-term suppression of IgE and relief of symptoms for severe allergic diseases. The transmembrane form of IgE (mIgE), which is present on all IgE-producing cells, serves as an excellent molecular target for ACT that employs chimeric antigen receptors (CARs). Here, we designed and tested CARs that use the extracellular domain of high affinity IgE receptor, FcεRIα, for mIgE recognition. When expressed on Jurkat T cells, FcεRIα-based CARs mediated robust responses in terms of CD69 upregulation to U266 myeloma cells expressing low levels of mIgE. FcεRIα-based CARs specifically recognized cells expressing mIgE, but not cells with secreted IgE captured through Fcε receptors. CAR+ Jurkat cells did not respond to LAD2 mast cells with secreted IgE bound through FcεRI or Ramos cells with secreted IgE bound through FcεRII. Co-culture of CAR+ Jurkat cells and LAD2 mast cells with IgE bound did not trigger LAD2 cell degranulation. The activity of CAR using wild type FcεRIα for mIgE binding was inhibited by the presence secreted IgE, which likely blocked CAR-mIgE interaction. The activities of CARs using low affinity mutants of FcεRIα, however, tolerated secreted IgE at relatively high concentrations. Moreover, primary human CD8+ T cells expressing a low affinity mutant CAR responded to U266 cells with INFγ production and cytotoxicity despite the presence of secreted IgE. The potency, specificity, and robustness of our CAR design, combined with repaid advances in the safety of ACT, hold promise for novel and highly effective cell-based therapies against severe allergic diseases." @default.
• W2897548738 created "2018-10-26" @default.
• W2897548738 creator A5042750822 @default.
• W2897548738 creator A5059147341 @default.
• W2897548738 creator A5059793510 @default.
• W2897548738 creator A5067550803 @default.
• W2897548738 creator A5083786449 @default.
• W2897548738 date "2018-10-10" @default.
• W2897548738 modified "2023-10-18" @default.
• W2897548738 title "Chimeric Antigen Receptors Based on Low Affinity Mutants of FcεRI Re-direct T Cell Specificity to Cells Expressing Membrane IgE" @default.
• W2897548738 cites W1494211513 @default.
• W2897548738 cites W1507361659 @default.
• W2897548738 cites W1561015496 @default.
• W2897548738 cites W1576093064 @default.
• W2897548738 cites W165646633 @default.
• W2897548738 cites W1669102459 @default.
• W2897548738 cites W1753684754 @default.
• W2897548738 cites W1857685991 @default.
• W2897548738 cites W1910182345 @default.
• W2897548738 cites W1963522404 @default.
• W2897548738 cites W1966542058 @default.
• W2897548738 cites W1969686552 @default.
• W2897548738 cites W1970166280 @default.
• W2897548738 cites W1971068808 @default.
• W2897548738 cites W1976112622 @default.
• W2897548738 cites W1978120677 @default.
• W2897548738 cites W1981092530 @default.
• W2897548738 cites W1988382766 @default.
• W2897548738 cites W1989273697 @default.
• W2897548738 cites W2004676991 @default.
• W2897548738 cites W2009342716 @default.
• W2897548738 cites W2010581292 @default.
• W2897548738 cites W2010803340 @default.
• W2897548738 cites W2020021662 @default.
• W2897548738 cites W2025041034 @default.
• W2897548738 cites W2028563109 @default.
• W2897548738 cites W2035302322 @default.
• W2897548738 cites W2042450529 @default.
• W2897548738 cites W2044914234 @default.
• W2897548738 cites W2049974202 @default.
• W2897548738 cites W2060545946 @default.
• W2897548738 cites W2063906189 @default.
• W2897548738 cites W2064719289 @default.
• W2897548738 cites W2066531673 @default.
• W2897548738 cites W2066756933 @default.
• W2897548738 cites W2092836519 @default.
• W2897548738 cites W2093168673 @default.
• W2897548738 cites W2093460937 @default.
• W2897548738 cites W2104597364 @default.
• W2897548738 cites W2105400883 @default.
• W2897548738 cites W2115518909 @default.
• W2897548738 cites W2120948675 @default.
• W2897548738 cites W2122465970 @default.
• W2897548738 cites W2124301452 @default.
• W2897548738 cites W2130011407 @default.
• W2897548738 cites W2130338247 @default.
• W2897548738 cites W2134422640 @default.
• W2897548738 cites W2153520524 @default.
• W2897548738 cites W2156278784 @default.
• W2897548738 cites W2160827724 @default.
• W2897548738 cites W2167550136 @default.
• W2897548738 cites W2170482067 @default.
• W2897548738 cites W2171026343 @default.
• W2897548738 cites W2406400390 @default.
• W2897548738 cites W2430242855 @default.
• W2897548738 cites W2589417329 @default.
• W2897548738 cites W2605626471 @default.
• W2897548738 cites W2609239470 @default.
• W2897548738 cites W2626153771 @default.
• W2897548738 cites W2755753624 @default.
• W2897548738 cites W2769297636 @default.
• W2897548738 cites W2818540548 @default.
• W2897548738 cites W91214138 @default.
• W2897548738 doi "https://doi.org/10.3389/fimmu.2018.02231" @default.
• W2897548738 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6191488" @default.
• W2897548738 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30364107" @default.
• W2897548738 hasPublicationYear "2018" @default.
• W2897548738 type Work @default.
• W2897548738 sameAs 2897548738 @default.
• W2897548738 citedByCount "13" @default.
• W2897548738 countsByYear W28975487382019 @default.
• W2897548738 countsByYear W28975487382020 @default.
• W2897548738 countsByYear W28975487382021 @default.
• W2897548738 countsByYear W28975487382022 @default.
• W2897548738 countsByYear W28975487382023 @default.
• W2897548738 crossrefType "journal-article" @default.
• W2897548738 hasAuthorship W2897548738A5042750822 @default.
• W2897548738 hasAuthorship W2897548738A5059147341 @default.
• W2897548738 hasAuthorship W2897548738A5059793510 @default.
• W2897548738 hasAuthorship W2897548738A5067550803 @default.
• W2897548738 hasAuthorship W2897548738A5083786449 @default.
• W2897548738 hasBestOaLocation W28975487381 @default.
• W2897548738 hasConcept C1122143 @default.
• W2897548738 hasConcept C141105273 @default.
• W2897548738 hasConcept C147483822 @default.
• W2897548738 hasConcept C153911025 @default.
• W2897548738 hasConcept C159654299 @default.
• W2897548738 hasConcept C170493617 @default.
• W2897548738 hasConcept C179464577 @default.
• W2897548738 hasConcept C185592680 @default.

• next